PDCD1 and neoplasm: As for immunotherapy, antibodies targeting PD-1, PD-L1 and CTLA4 have been confirmed to make a significant improvement in the survival outcomes of patients with tumors, and the combination therapy targeting CTLA4 and PD-1 further improves the response rates and median survival of patients with many tumor types54,55.